Kiniksa Pharmaceuticals Ltd. Class A (KNSA) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kiniksa Pharmaceuticals Ltd. Class A may confront increased business risk due to the more stringent shareholder voting requirements in the UK compared to Bermuda. The company’s directors currently have the ability to issue shares without shareholder consent under Bermuda law, a flexibility not mirrored in the UK where shareholder authorization is needed every five years. Additionally, English law’s statutory preemptive rights and the requirement for a 75% shareholder vote to waive these rights could limit Kiniksa’s capacity to raise capital expeditiously. The potential inability to renew these authorizations could materially impact Kiniksa’s operations and financial health.
Overall, Wall Street has a Strong Buy consensus rating on KNSA stock based on 5 Buys.
To learn more about Kiniksa Pharmaceuticals Ltd. Class A’s risk factors, click here.